Agilix Corporation (main assets acquired byPerkin-Elmer), a New Haven, CT, leading developer of next generation functional genomics and proteomics platform technologies for the systematic discovery and analysis of genes, their protein products and related biological functions. Its technologies and services help reduce the risk, cost and time to market for new pharmaceutical, biotechnology and agricultural products.
Dynavax Technologies(Nasdaq: DVAX)a Berkeley, CA, is a clinical-stage biopharmaceutical company which discovers and develops noval products to prevent and treat infectious and inflammatory diseases. Its lead prodcut candidate HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doese than currently licensed vaccines.
Idun Pharmaceuticals(acquired by Pfizer), a San Diego, CA, biopharmaceutical company creating innovative human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. It was developing drugs to treat liver disease, inflammation, cancer, and cardiovascular disease.
Kiadis Pharmaceuticals (AMS: KDS),a Netherlands based clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.
Memory Pharmaceuticals(NASDAQ: previously listed as MEMY;acquired by ROCHE), a Montvale, NJ, neuropharmaceutical drug development company working in the field of learning and memory disorders. Its proprietary COGNOSTICSTM technology platform consists of state-of-the-art bioassays that evaluate the biological, physiological and behavioral aspects of drug effects within relevant memory pathways.
NeuroVision, a Singapore headquartered company applying novel technology to improving eyesight without surgery or drugs. Its Neural Vision Correction technology is a non-invasive, patient specific, computerised treatment based on visual stimulation of the neural connections responsible for vision. Its technology and licences have been acquired in a private transaction by a US company.
Renovis (NASDAQ: previously listed as RNVS; merged with Evotec)a San Francisco, CA, biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for neurological disease. Renovis industrializes neurobiology using proprietary technologies for overcoming nervous system complexity; unique expertise in neuronal identification, isolation, and neurogenomics; relevant preclinical animal models; cutting-edge electrophysiology; and specialized chemistry to discover and develop new drugs for neurological diseases and disorders.
Renovo(LSE: previously listed as RNVO) aManchester, UKbased biopharmaceutical company focused on discovery, development and commercialization of drugs that prevent scarring and promote wound healing. The company has conducted extensive clinical trials with products to prevent scar formation and accelerate healing. Its innovative products and technologies are based on a portfolio of over 300 patents and patent applications worldwide.